Publications by authors named "A Elgart"

Claim this Profile
P
Population Pharmacokinetic Modeling of TV-46000, a Risperidone Long-Acting Subcutaneous Antipsychotic for the Treatment of Patients with Schizophrenia.
Itay Perlstein, Avia Merenlender Wagner, Anna Elgart, Anthe S Zandvliet, Farina Hellmann

Neurol Ther· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TV-46000, A Long-Acting Subcutaneous Antipsychotic Agent, Demonstrated Improved Patient-Centered Outcomes in Patients with Schizophrenia.
Leslie Citrome, Mark Suett, Kelli R Franzenburg, Roy Eshet, Anna Elgart

Neuropsychiatr Dis Treat· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Long-Term Safety and Tolerability Study of TV-46000 for Subcutaneous Use in Patients with Schizophrenia: A Phase 3, Randomized, Double-Blinded Clinical Trial.
John M Kane, Roy Eshet, Eran Harary, Orna Tohami, Anna Elgart

CNS Drugs· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population Pharmacokinetic Modeling and Simulation of TV-46000: A Long-Acting Injectable Formulation of Risperidone.
Itay Perlstein, Avia Merenlender Wagner, Roberto Gomeni, Michael Lamson, Eran Harary, Anna Elgart

Clin Pharmacol Drug Dev· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Effect of CYP3A Induction and Inhibition on the Pharmacokinetics of Laquinimod, a Novel Neuroimmunomodulator.
Anna Elgart, David J Greenblatt, Pippa S Loupe, Arik A Zur, Sivan Weiss

Clin Pharmacol Drug Dev· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis